Thrombolytic therapy in acute ischemic stroke - Basic concepts

Current Vascular Pharmacology

Volumn 4, Issue 1, 2006, Pages 31-44

  Meretoja, Atte ^a   Tatlisumak, Turgut ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cerebral infarction; Hemorrhage; Recanalization; Stroke; t PA; Thrombolysis; Thrombolytic therapy; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESMOTEPLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DUTEPLASE; GLYCERYL TRINITRATE; HEPARIN; LANOTEPLASE; MICROPLASMIN; PAMITEPLASE; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; FIBRINOLYTIC AGENT;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTERY THROMBOSIS; BASILAR ARTERY; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CLEARANCE; DRUG COST; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; FIBRIN CLOT; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEMATOTHORAX; HUMAN; LIP DISEASE; LOADING DRUG DOSE; META ANALYSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT SELECTION; PLEURA EMPYEMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; THROMBECTOMY; TONGUE EDEMA; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; ADJUVANT CHEMOTHERAPY; CLASSIFICATION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MULTICENTER STUDY; PHYSIOLOGY;

BLOOD COAGULATION; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY, ADJUVANT; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33644870186     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106775203108     Document Type: Review

References (206)

1. Sussmann BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral artery occlusion. JAMA 1958; 167: 1705-9.
2. Clarke RL, Cliffton EE. The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. Am J Cardiol 1960; 6: 546-51.
3. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 1963; 13: 927-37.
4. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003: CD000213.
5. Schellinger PD, Kaste M, Hacke W. An update on thrombolytic therapy for acute stroke. Curr Opin Neurol 2004; 17: 69-77.
6. Horowitz SH. Thrombolytic therapy in acute stroke: neurologists, get off your hands! Arch Neurol 1998; 55: 155-7.
7. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
8. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
9. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet 2003; 362: 1211-24.
10. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
11. Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, et al. Transient ischemic attack - proposal for a new definition. N Engl J Med 2002; 347: 1713-6.
12. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003; 34: 575-83.
13. Rantanen K, Tatlisumak T. Secondary prevention of ischemic stroke. Curr Drug Targets 2004; 5: 457-72.
14. Archer CR, Horenstein S. Basilar artery occlusion: clinical and radiological correlation. Stroke 1977; 8: 383-90.
15. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-22.
16. Brandt T. Diagnosis and thrombolytic therapy of acute basilar artery occlusion: a review. Clin Exp Hypertens 2002; 24: 611-22.
17. Brandt T, von Kummer R, Muller-Kuppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 1996; 27: 875-81.
18. Lindsberg PJ, Soinne L, Tatlisumak T, Roine RO, Kallela M, Happola O, et al. Long-term outcome after intravenous thrombolysis of basilar artery occlusion. JAMA 2004; 292: 1862-6.
19. Masuhr F, Mehraein S, Einhaupl K. Cerebral venous and sinus thrombosis. J Neurol 2004; 251: 11-23.
20. Soleau SW, Schmidt R, Stevens S, Osborn A, MacDonald JD. Extensive experience with dural sinus thrombosis. Neurosurgery 2003; 52: 534-44.
21. Bousser MG. Cerebral venous thrombosis: nothing, heparin, or local thrombolysis? Stroke 1999; 30: 481-3.
22. Seifert V. Intrathecal fibrinolysis using recombinant tissue plasminogen activator (rTPA) for prevention of cerebral vasospasm and delayed ischaemic deficits after aneurysmal subarachnoid haemorrhage. Experimental and clinical data. Neurol Res 1994; 16: 54-8.
23. Findlay JM, Kassell NF, Weir BK, Haley EC, Jr., Kongable G, Germanson T, et al. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995; 37: 168-76.
24. Naff NJ, Hanley DF, Keyl PM, Tuhrim S, Kraut M, Bederson J, et al. Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 2004; 54: 577-83; discussion 583-4.
25. Findlay JM, Jacka MJ. Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage. Neurosurgery 2004; 55: 532-7; discussion 537-8.
26. Virchow R. Phlogose und Thrombose. In: Virchow R, editor. Gesammelte Abhandlungen zur Wissenschaflichen Medizin. Frankfurt: Van Meidlinger Sohn; 1856. p. 458-636.
27. Astrup T. The biological significance of fibrinolysis. Lancet 1956; 271: 565-8.
28. Astrup T. The haemostatic balance. Thromb Diath Haemorrh 1958; 2: 347-57.
29. Tatlisumak T, Fisher M. Hematologic disorders associated with ischemic stroke. J Neurol Sci 1996; 140: 1-11.
30. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 2000; 26: 605-18.
31. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL. Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002; 12: 317-24.
32. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28: 555-68.
33. Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 216-29.
34. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004; 35: 212-27.
35. al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46: 343-7.
36. Price GC, Thompson SA, Kam PC. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004; 59: 483-92.
37. Hack CE. Tissue factor pathway of coagulation in sepsis. Crit Care Med 2000; 28: S25-30.
38. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
39. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
40. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
41. Nesheim M. Thrombin and fibrinolysis. Chest 2003; 124: 33S-9S.
42. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004; 61: 873-85.
43. del Zoppo GJ. Thrombolysis: from the experimental findings to the clinical practice. Cerebrovasc Dis 2004; 17 Suppl 1: 144-52.
44. Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997; 139: 245-56.
45. Teesalu T, Kulla A, Asser T, Koskiniemi M, Vaheri A. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem Soc Trans 2002; 30: 183-9.
46. Jern C, Blomstrand C, Westerlind A. Evidence of a net release of tissue-type plasminogen activator across the human cerebral vasculature. Thromb Haemost 2004; 91: 1019-25.
47. Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19: 1071-5.
48. Gerard RD, Chien KR, Meidell RS. Molecular biology of tissue plasminogen activator and endogenous inhibitors. Mol Biol Med 1986; 3: 449-57.
49. Jornvall H, Pohl G, Bergsdorf N, Wallen P. Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogeneity. FEBS Lett 1983; 156: 47-50.
50. Degen SJ, Rajput B, Reich E. The human tissue plasminogen activator gene. J Biol Chem 1986; 261: 6972-85.
51. Fisher R, Waller EK, Grossi G, Thompson D, Tizard R, Schleuning WD. Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5′ flanking region. J Biol Chem 1985; 260: 11223-30.
52. Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A 1984; 81: 5355-9.
53. Bell WR. Present-day thrombolytic therapy: therapeutic agents - pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002; 3 Suppl 2: S34-44.
54. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost 1995; 74: 387-90.
55. Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A 1983; 80: 6804-8.
56. Zito RA, Reid PR. Lidocaine kinetics predicted by indocyanine green clearance. N Engl J Med 1978; 298: 1160-3.
57. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, et al. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. Circulation 1989; 80: 1222-30.
58. Monard D. Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends Neurosci 1988; 11: 541-4.
59. Seeds NW, Haffke S, Christensen K, Schoonmaker J. Cerebellar granule cell migration involves proteolysis. Adv Exp Med Biol 1990; 265: 169-78.
60. Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D, et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999; 18: 3007-12.
61. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
62. Siao CJ, Fernandez SR, Tsirka SE. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 2003; 23: 3234-42.
63. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003; 23: 8867-71.
64. Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Leveille F, Cacquevel M, Plawinski L, et al. Is tissue-type plasminogen activator a neuromodulator? Mol Cell Neurosci 2004; 25: 594-601.
65. Horrevoets AJG, Pannekoek H, Nesheim ME. A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated. J Biol Chem 1996; 272: 2183-91.
66. Nesheim M, Walker J, Wang W, Boffa M, Horrevoets A, Bajzar L. Modulation of fibrin cofactor activity in plasminogen activation. Ann N Y Acad Sci 2001; 936: 247-60.
67. Bringmann P, Gruber D, Liese A, Toschi L, Kratzchmar J, Schleuning WD, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25596-603.
68. Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54: 684-7.
69. Huber K, Rosc D, Resch I, Schuster E, Glogar DH, Kaindl F, et al. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 1988; 60: 372-6.
70. Akiyama Y, Kazama M, Tahara C, Shimazu C, Otake J, Kamei K, et al. Reference values of hemostasis related factors of healthy Japanese adults. I: Circadian fluctuation. Thromb Res 1990; 60: 281-9.
71. Muller JE. Circadian variation in cardiovascular events. Am J Hypertens 1999; 12: 35S-42S.
72. Stergiou GS, Vemmos KN, Pliarchopoulou KM, Synetos AG, Roussias LG, Mountokalakis TD. Parallel morning and evening surge in stroke onset, blood pressure, and physical activity. Stroke 2002; 33: 1480-6.
73. Spengos K, Vemmos KN, Tsivgoulis G, Synetos A, Zakopoulos NA, Zis VP, et al. Two-peak temporal distribution of stroke onset in Greek patients. a hospital-based study. Cerebrovasc Dis 2003; 15: 70-7.
74. Kono T, Morita H, Nishina T, Fujita M, Hirota Y, Kawamura K, et al. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. J Am Coll Cardiol 1996; 27: 774-8.
75. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995; 91: 1341-6.
76. Goldhammer E, Kharash L, Abinader EG. Circadian fluctuations in the efficacy of thrombolysis with streptokinase. Postgrad Med J 1999; 75: 667-71.
77. Ohkuwa T, Itoh H, Yamamoto T, Yamazaki Y. Comparison of tPA and u-PA levels in maximal treadmill and deep-water running. Prev Med 2004; 39: 177-81.
78. Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost 1989; 62: 767-71.
79. Cohen AF, Burggraaf K, de Boer A, Kluft C. Clearance of plasminogen activator - a major determinant of plasma concentration: therapeutic and diagnostic implications. Ann N Y Acad Sci 1992; 667: 443-9.
80. Larsson PT, Wiman B, Olsson G, Angelin B, Hjemdahl P. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis. Thromb Haemost 1990; 63: 482-7.
81. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001; 103: 1936-41.
82. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4: 228-31.
83. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003; 34: 2025-30.
84. Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, et al. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1999; 19: 1316-21.
85. Klein GM, Li H, Sun P, Buchan AM. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology 1999; 52: 1381-4.
86. Barlow GH. Urinary and kidney cell plasminogen activator (urokinase). Methods Enzymol 1976; 45: 239-44.
87. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936: 226-36.
88. Huber K. Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis 2001; 11: 195-202.
89. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004; 91: 1146-51.
90. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-8.
91. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor-1. Blood 2004; prepublished online Aug 17.
92. Eto M, Luscher TF. Modulation of coagulation and fibrinolytic pathways by statins. Endothelium 2003; 10: 35-41.
93. Bonnar J, Daly L, Sheppard BL. Changes in the fibrinolytic system during pregnancy. Semin Thromb Hemost 1990; 16: 221-9.
94. Kruithof EK. Plasminogen activator inhibitors - a review. Enzyme 1988; 40: 113-21.
95. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-22.
96. Brott T. Thrombolytic therapy for stroke. Cerebrovasc Brain Metab Rev 1991; 3: 91-113.
97. del Zoppo GJ, Pessin MS, Mori E, Hacke W. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin Neurol 1991; 11: 368-84.
98. Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med 2002; 3 Suppl 2: S25-33.
99. Silver B, Weber J, Fisher M. Medical therapy for ischemic stroke. Clin Neuropharmacol 1996; 19: 101-28.
100. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
101. Tillett WS, Sherry S, Christensen LR, Johnson A, Hazlehurst G. Streptococcal enzymatic depridement. Ann Surg 1949; 131: 12-22.
102. Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jick S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959; 38: 1111-9.
103. Johnson AJ, Mc CW. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest 1959; 38: 1627-43.
104. van de Loo JC. Historical perspectives on thrombolytic therapy. Thromb Haemost 1999; 82: 971-3.
105. Bajaj AP, Castellino FJ. Activation of human plasminogen by equimolar levels of streptokinase. J Biol Chem 1977; 252: 492-8.
106. Sundram V, Nanda JS, Rajagopal K, Dhar J, Chaudhary A, Sahni G. Domain truncation studies reveal that the streptokinase-plasmin activator complex utilizes long range protein-protein interactions with macromolecular substrate to maximize catalytic turnover. J Biol Chem 2003; 278: 30569-77.
107. Banerjee A, Chisti Y, Banerjee UC. Streptokinase - a clinically useful thrombolytic agent. Biotechnol Adv 2004; 22: 287-307.
108. Monk JP, Heel RC. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction. Drugs 1987; 34: 25-49.
109. Been M, de Bono DP, Muir AL, Boulton FE, Fears R, Standring R, et al. Clinical effects and kinetic properties of intravenous APSAC - anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction. Int J Cardiol 1986; 11: 53-61.
110. Johnson ES, Cregeen RJ. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). Drugs 1987; 33 Suppl 3: 298-311.
111. Morris AD, Ritchie C, Grosset DG, Adams FG, Lees KR. A pilot study of streptokinase for acute cerebral infarction. QJM 1995; 88: 727-31.
112. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Lancet 1995; 346: 1509-14.
113. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial - Europe Study Group. N Engl J Med 1996; 335: 145-50.
114. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276: 961-6.
115. Cornu C, Boutitie F, Candelise L, Boissel JP, Donnan GA, Hommel M, et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31: 1555-60.
116. Verstraete M. Biochemical and clinical aspects of thrombolysis. Semin Hematol 1978; 15: 35-54.
117. Wijngaards G, Rijken DC, van Wezel AL, Groeneveld E, van der Velden CA. Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 749-60.
118. Gurewich V, Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of nonselectivity. Thromb Res 1986; 44: 217-28.
119. Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem 1985; 260: 12382-9.
120. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-23.
121. Hanaway J, Torack R, Fletcher AP, Landau WM. Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 1976; 7: 143-6.
122. Gonner F, Remonda L, Mattle H, Sturzenegger M, Ozdoba C, Lovblad KO, et al. Local intra-arterial thrombolysis in acute ischemic stroke. Stroke 1998; 29: 1894-900.
123. Eckert B, Kucinski T, Neumaier-Probst E, Fiehler J, Rother J, Zeumer H. Local intra-arterial fibrinolysis in acute hemispheric stroke: effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome. Cerebrovasc Dis 2003; 15: 258-63.
124. Zaidat OO, Suarez JI, Santillan C, Sunshine JL, Tarr RW, Paras VH, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002; 33: 1821-6.
125. Arnold M, Schroth G, Nedeltchev K, Loher T, Remonda L, Stepper F, et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 2002; 33: 1828-33.
126. Takano K, Carano RA, Tatlisumak T, Meiler M, Sotak CH, Kleinert HD, et al. Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging. Neurology 1998; 50: 870-5.
127. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998; 29: 4-11.
128. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999; 282: 2003-11.
129. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932-6.
130. Wagstaff AJ, Gillis JC, Goa KL. Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Drugs 1995; 50: 289-316.
131. Hamilton MG, Lee JS, Cummings PJ, Zabramski JM. A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits. Stroke 1994; 25: 651-5; discussion 656.
132. de Boer A, van Griensven JM. Drug interactions with thrombolytic agents. Current perspectives. Clin Pharmacokinet 1995; 28: 315-26.
133. Nicolini FA, Ferrini D, Ottani F, Galvani M, Ronchi A, Behrens PH, et al. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. Am J Cardiol 1994; 74: 662-6.
134. Lindsberg PJ, Soinne L, Roine RO, Salonen O, Tatlisumak T, Kallela M, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003; 34: 1443-9.
135. Molinaro G, Gervais N, Adam A. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 2002; 33: 1712-6.
136. Hill MD, Lye T, Moss H, Barber PA, Demchuk AM, Newcommon NJ, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003; 60: 1525-7.
137. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329: 673-82.
138. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991; 115: 256-65.
139. Ciccone A. Consent to thrombolysis in acute ischaemic stroke: from trial to practice. Lancet Neurol 2003; 2: 375-8.
140. Brott TG, Haley EC, Jr., Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-40.
141. Haley EC, Jr., Brott TG, Sheppard GL, Barsan W, Broderick J, Marler JR, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. Stroke 1993; 24: 1000-4.
142. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-82.
143. Yamaguchi T, Hayakawa T, Kiuchi H. Japanese Thrombolysis Study Group: Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993; 3: 269-272.
144. Boysen G, Overgaard K, Sperling B, Pedersen H, Gam J, Ellemann K. Alteplase therapy in acute ischemic stroke: a Danish pilot study. Z Kardiol 1993; 82 Suppl 2: 105-8.
145. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992; 23: 646-52.
146. Hennerici M, Hacke W, von Kummer R, Hornig C, Zangemeister W. Intravenous tissue plasminogen activator for the treatment of acute thromboembolic ischemia. Cerebrovasc Dis 1991; 1: 124-8.
147. Haley EC, Jr., Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-5.
148. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
149. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-25.
150. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-51.
151. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Stroke 2000; 31: 811-6.
152. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Jama 1999; 282: 2019-26.
153. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, et al. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke 1998; 29: 2073-5.
154. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet 2004; 363: 768-74.
155. Ramee SR, Subramanian R, Felberg RA, McKinley KL, Jenkins JS, Collins TJ, et al. Catheter-based treatment for patients with acute ischemic stroke ineligible for intravenous thrombolysis. Stroke 2004; 35: e109-11.
156. Bourekas EC, Slivka AP, Shah R, Sunshine J, Suarez JI. Intraarterial thrombolytic therapy within 3 hours of the onset of stroke. Neurosurgery 2004; 54: 39-44.
157. Hawkey C. Plasminogen activator in saliva of the vampire bat Desmodus rotundus. Nature 1966; 211: 434-5.
158. Stubbs MT, Renatus M, Bode W. An active zymogen: unravelling the mystery of tissue-type plasminogen activator. Biol Chem 1998; 379: 95-103.
159. Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989; 264: 17947-52.
160. Petri T, Langer G, Bringmann P, Cashion L, Shallow S, Schleuning WD, et al. Production of vampire bat plasminogen activator DSPA alpha 1 in CHO and insect cells. J Biotechnol 1995; 39: 75-83.
161. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-43.
162. Cliffton EE. The use of plasmin in humans. Ann New York Acad Sci 1957; 68: 209-229.
163. Collen D. Revival of plasmin as a therapeutic agent? Thromb Haemost 2001; 86: 731-2.
164. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke 2002; 33: 2279-84.
165. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-45.
166. Parry MA, Jacob U, Huber R, Wisner A, Bon C, Bode W. The crystal structure of the novel snake venom plasminogen activator TSV-PA: a prototype structure for snake venom serine proteinases. Structure 1998; 6: 1195-206.
167. Park D, Kim H, Chung K, Kim DS, Yun Y. Expression and characterization of a novel plasminogen activator from Agkistrodon halys venom. Toxicon 1998; 36: 1807-19.
168. Sanchez EF, Santos CI, Magalhaes A, Diniz CR, Figueiredo S, Gilroy J, et al. Isolation of a proteinase with plasminogen-activating activity from Lachesis muta muta (bushmaster) snake venom. Arch Biochem Biophys 2000; 378: 131-41.
169. Rabijns A, De Bondt HL, De Ranter C. Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential. Nat Struct Biol 1997; 4: 357-60.
170. Jespers L, Vanwetswinkel S, Lijnen HR, Van Herzeele N, Van Hoef B, Demarsin E, et al. Structural and functional basis of plasminogen activation by staphylokinase. Thromb Haemost 1999; 81: 479-85.
171. Nagai N, Vanlinthout I, Collen D. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 1999; 100: 2541-6.
172. Vanderschueren S, Van Vlaenderen I, Collen D. Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model. Stroke 1997; 28: 1783-8.
173. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-3.
174. Moreadith RW, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev 2003; 55: 1337-45.
175. Malcolm AD, Keltai M, Walsh MJ. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. Eur Heart J 1996; 17: 1522-31.
176. Oikawa K, Watanabe T, Miyamoto I, Higuchi S. Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma. Xenobiotica 2000; 30: 993-1003.
177. Suzuki Y, Kano T, Katayama Y, Tejima E, Harada T. Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life. Neurol Res 2003; 25: 477-80.
178. Noble S, McTavish D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 1996; 52: 589-605.
179. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89: 1358-62.
180. Qureshi AI, Siddiqui AM, Kim SH, Hanel RA, Xavier AR, Kirmani JF, et al. Reocclusion of recanalized arteries during intraarterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol 2004; 25: 322-8.
181. Qureshi AI, Siddiqui AM, Suri MF, Kim SH, Ali Z, Yahia AM, et al. Aggressive mechanical clot disruption and low-dose intraarterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002; 51: 1319-27.
182. Davydov L, Cheng JW. Tenecteplase: a review. Clin Ther 2001; 23: 982-97.
183. Dunn CJ, Goa KL. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am J Cardiovasc Drugs 2001; 1: 51-66.
184. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999; 354: 716-22.
185. Van de Werf F, Barron HV, Armstrong PW, Granger CB, Berioli S, Barbash G, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001; 22: 2253-61.
186. Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 2004; 188: 279-85.
187. Nordt TK, Moser M, Kohler B, Kubler W, Bode C. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost 1999; 82 Suppl 1: 121-3.
188. Umemura K, Ishiye M, Kosuge K, Nakashima M. Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model. Eur J Pharmacol 1995; 275: 17-21.
189. Alexandrov AV, Bladin CF, Norris JW. Intracranial blood flow velocities in acute ischemic stroke. Stroke 1994; 25: 1378-83.
190. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke 2000; 31: 1812-6.
191. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies - the need for new approaches. Cerebrovasc Dis 2004; 17 Suppl 1: 153-66.
192. Lindsberg PJ, Roine RO, Tatlisumak T, Sairanen T, Kaste M. The future of stroke treatment. Neurol Clin 2000; 18: 495-510.
193. Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999; 81: 605-12.
194. Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC. Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial. J Neuroimaging 2004; 14: 113-7.
195. Alexandrov AV. Ultrasound identification and lysis of clots. Stroke 2004; 35: 2722-5.
196. Heo JH, Lee KY, Kim SH, Kim DI. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003; 60: 1684-7.
197. Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004; 363: 804-13.
198. Boulos AS, Levy EI, Bendok BR, Kim SH, Qureshi AI, Guterman LR, et al. Evolution of neuroendovascular intervention: a review of advancement in device technology. Neurosurgery 2004; 54: 438-52; discussion 452-3.
199. Toni D, Chamorro A, Kaste M, Lees K, Wahlgren NG, Hacke W. Acute treatment of ischaemic stroke. European Stroke Initiative. Cerebrovasc Dis 2004; 17 Suppl 2: 30-46.
200. Adams HP, Jr., Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34: 1056-83.
201. Grierson DS, Bjornsson TD. Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity. Clin Pharmacol Ther 1987; 41: 304-13.
202. de Boer A, Kluft C, Gerloff J, Dooijewaard G, Gunzler WA, Beier H, et al. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. Thromb Haemost 1993; 70: 320-5.
203. Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-6.
204. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41: 1229-45.
205. Liao WC, Beierle FA, Stouffer BC, Dockens RC, Abbud ZA, Tay LK, et al. Single Bolus Regimen of Lanoteplase (nPA) in Acute Myocardial Infarction: Pharmacokinetic Evaluation from inTime-I Study. Circulation 1997; 96: 260-I-261-I.
206. Sobel BE. Fibrin specificity of plasminogen activators, rebound generation of thrombin, and their therapeutic implications. Coron Artery Dis 2001; 12: 323-32.